The 2003 Israeli Soy-Formula Thiamine-Deficiency Outbreak

2003 Israeli soy-formula thiamine outbreak — scientific infographic poster

In October and November of 2003, paediatric intensive-care units across Israel began admitting previously healthy infants with an unfamiliar pattern of acute heart failure, hypotonia, aphonia, and ophthalmoplegia. Three died in the acute illness, and a fourth child, left in a chronic vegetative state, died six years later (Mimouni-Bloch 2014). The source was identified on November 6, 2003, when a 5.5-month-old boy was admitted to Tel Aviv Sourasky Medical Center with upbeat nystagmus, eye-movement paralysis (ophthalmoplegia) and vomiting. The team there, which included paediatric neurologist Aviva Fattal-Valevski, suspected Wernicke's encephalopathy, started thiamine, and saw him improve within hours; his feeding history connected the cases to a single common exposure: a soy-based infant formula made in Germany for the Israeli market. Testing by the Israeli public health authorities found the formula's thiamine undetectable (below 0.5 µg per gram), and the product was pulled from the shelves (Fattal-Valevski 2005). The 2003 outbreak remains the largest and best-documented modern incident of formula-induced infantile thiamine deficiency, and it permanently changed how infant formula is regulated worldwide. Long-term follow-up of the surviving cohort has shown that even children clinically "recovered" from acute thiamine deficiency frequently carry lifelong neurodevelopmental sequelae — particularly expressive language impairment, refractory epilepsy, motor deficits, and visual abnormalities.

Table of Contents

  1. The Product and the Company
  2. The Manufacturing Error
  3. Timeline of the Outbreak
  4. Clinical Recognition
  5. Clinical Presentations
  6. The Three Deaths
  7. Regulatory and Public-Health Response
  8. Legal Aftermath
  9. Long-Term Follow-Up of Survivors
  10. Global Impact on Infant Formula Regulation
  11. Lessons for Clinicians
  12. Key Research Papers
  13. Connections
  14. Featured Videos

1. The Product and the Company

The formula was sold by an Israeli infant-formula distributor, which did not manufacture its own product; a German manufacturer made it under the distributor's label. A 2012 review describes it as produced in Germany and marketed exclusively in Israel (Shamir 2012).

2. The Manufacturing Error

The formula's maker had recently reformulated the vitamin and mineral premix used in the product. The reformulation reduced the thiamine content of the premix to a level so low that the finished formula contained essentially no detectable thiamine. The error was a single-point failure in the vitamin premix specification, compounded by inadequate end-product analytical testing.

3. Timeline of the Outbreak

4. Clinical Recognition

The recognition of the 2003 outbreak is a model of pattern-recognition clinical epidemiology. None of the individual cases would have raised the alarm on its own — each looked like a sporadic case of unexplained cardiomyopathy or encephalopathy. The signal came from a single index case: the finding of gaze abnormalities in one infant by neuro-ophthalmologists led to the unravelling of the epidemic (Kesler 2005), and one clinical team's willingness to entertain a common nutritional cause.

The first signs were vague. Among the 9 infants in the outbreak team's series, the early symptoms were vomiting (8 infants), lethargy (7), irritability (5), a swollen belly (abdominal distension, 4), diarrhoea (4), breathing symptoms (4), developmental delay (3) and failure to thrive (2). Every one of the 9 also had an infection, most of them mild. When the Ministry of Health screened 156 infants who had been fed the formula, 8 more had abnormal thiamine tests; their parents had noticed no symptoms, although the examining doctors documented irritability, lethargy, vomiting, poor appetite, failure to thrive and developmental delay (Fattal-Valevski 2005).

5. Clinical Presentations

Fattal-Valevski's 2005 Pediatrics report described 9 infants in the team's care (6 boys and 3 girls, aged 2 to 12 months): 3 had neurological signs and 6 did not. The 6 without neurological signs recovered completely within 2 to 3 weeks of thiamine treatment, and longer feeding with the formula was linked to failure to thrive. The 2014 follow-up report described acute brain illness (encephalopathy) in 11 children: 6 had bulbar signs (weakness of the brainstem-controlled muscles of voice, swallowing and breathing), 5 had eye signs, 2 had paralysis of the nerve to the diaphragm (phrenic neuropathy) and 5 had heart involvement (Mimouni-Bloch 2014). Across these reports the illness took overlapping forms that mirror the classical descriptions of beriberi and Wernicke encephalopathy, with infant-specific features.

6. The Three Deaths

Three Israeli infants died in the acute illness after being fed the thiamine-deficient formula. In the 2014 follow-up report all three had cardiomyopathy (Shoshin beriberi); a fourth child, left in a chronic vegetative state, died six years later (Mimouni-Bloch 2014). Their ages ranged from about three to seven months. Several additional infants survived initial cardiac arrest with cardiopulmonary resuscitation and progressed to long-term neurodevelopmental sequelae attributable to anoxic and metabolic brain injury combined with primary thiamine deficiency.

7. Regulatory and Public-Health Response

9. Long-Term Follow-Up of Survivors

The 2003 outbreak cohort has been followed by Fattal-Valevski and colleagues for more than a decade, producing the largest single body of evidence on the long-term neurodevelopmental consequences of acute infantile thiamine deficiency. The findings are sobering: even infants who appeared to recover completely in the acute phase have shown persistent and often progressive deficits as they aged into school years.

10. Global Impact on Infant Formula Regulation

11. Lessons for Clinicians

Key Research Papers

  1. Fattal-Valevski A, Kesler A, Sela BA, Nitzan-Kaluski D, Rotstein M, Mesterman R, Toledano-Alhadef H, Stolovitch C, Hoffmann C, Globus O, Eshel G. Outbreak of life-threatening thiamine deficiency in infants in Israel caused by a defective soy-based formula. Pediatrics. 2005;115(2):e233–e238. — doi:10.1542/peds.2004-1255 · PubMed PMID: 15687431
  2. Kornreich L, Bron-Harlev E, Hoffmann C, Schwarz M, Konen O, Schoenfeld T, Straussberg R, Nahum E, Ibrahim AK, Eshel G, Horev G. Thiamine deficiency in infants: MR findings in the brain. AJNR Am J Neuroradiol. 2005;26(7):1668–1674. — PubMed PMID: 16091511
  3. Fattal-Valevski A, Azouri-Fattal I, Greenstein YJ, Guindy M, Blau A, Zelnik N. Delayed language development due to infantile thiamine deficiency. Dev Med Child Neurol. 2009;51(8):629–634. — doi:10.1111/j.1469-8749.2008.03161.x · PubMed PMID: 19191836
  4. Fattal-Valevski A, Bloch-Mimouni A, Kivity S, Heyman E, Brezner A, Strausberg R, Inbar D, Kramer U, Goldberg-Stern H. Epilepsy in children with infantile thiamine deficiency. Neurology. 2009;73(11):828–833. — doi:10.1212/WNL.0b013e3181b121f5 · PubMed PMID: 19571254
  5. Mimouni-Bloch A, Goldberg-Stern H, Strausberg R, Brezner A, Heyman E, Inbar D, Kivity S, Zvulunov A, Sztarkier I, Fogelman R, Fattal-Valevski A. Thiamine deficiency in infancy: long-term follow-up. Pediatr Neurol. 2014;51(3):311–316. — doi:10.1016/j.pediatrneurol.2014.05.010 · PubMed PMID: 25160536
  6. Kesler A, Stolovitch C, Hoffmann C, Avni I, Morad Y. Acute ophthalmoplegia and nystagmus in infants fed a thiamine-deficient formula: an epidemic of Wernicke encephalopathy. J Neuroophthalmol. 2005;25(3):169–172. — doi:10.1097/01.wno.0000177293.06727.d5 · PubMed PMID: 16148620
  7. Shamir R. Thiamine-deficient infant formula: what happened and what have we learned? Ann Nutr Metab. 2012;60(3):185–187. — doi:10.1159/000338211 · PubMed PMID: 22699764
  8. Siegel-Itzkovich J. Police in Israel launch investigation into deaths of babies given formula milk. BMJ. 2003;327(7424):1128. — doi:10.1136/bmj.327.7424.1128-i · PubMed PMID: 14615325
  9. Aris B. Maker of vitamin B1-deficient baby milk admits error. Lancet. 2003;362(9397):1730. — doi:10.1016/S0140-6736(03)14890-8 · PubMed PMID: 14655665
  10. Harel Y, Zuk L, Guindy M, Nakar O, Lotan D, Fattal-Valevski A. The effect of subclinical infantile thiamine deficiency on motor function in preschool children. Matern Child Nutr. 2017;13(4):e12397. — doi:10.1111/mcn.12397 · PubMed PMID: 28133900
  11. Sechi G, Serra A. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442–455. — doi:10.1016/S1474-4422(07)70104-7 · PubMed PMID: 17434099
  12. Vasconcelos MM, Silva KP, Vidal G, Silva AF, Domingues RC, Berditchevsky CR. Early diagnosis of pediatric Wernicke's encephalopathy. Pediatr Neurol. 1999;20(4):289–294. — doi:10.1016/S0887-8994(98)00153-2 · PubMed PMID: 10328278
  13. Whitfield KC, Bourassa MW, Adamolekun B, Bergeron G, Bettendorff L, Brown KH, Cox L, Fattal-Valevski A, Fischer PR, Frank EL, Hiffler L, Hlaing LM, Jefferds ME, Kapner H, Kounnavong S, Mousavi MPS, Roth DE, Tsaloglou MN, Wieringa F, Combs GF Jr. Thiamine deficiency disorders: diagnosis, prevalence, and a roadmap for global control programs. Ann N Y Acad Sci. 2018;1430(1):3–43. — doi:10.1111/nyas.13919 · PubMed PMID: 30151974
  14. Marcé-Grau A, Martí-Sánchez L, Baide-Mairena H, Ortigoza-Escobar JD, Pérez-Dueñas B. Genetic defects of thiamine transport and metabolism: a review of clinical phenotypes, genetics, and functional studies. J Inherit Metab Dis. 2019;42(4):581–597. — doi:10.1002/jimd.12125 · PubMed PMID: 31095747

PubMed Topic Searches

  1. PubMed: Thiamine-deficient soy formula Israel
  2. PubMed: Fattal-Valevski thiamine
  3. PubMed: Soy formula thiamine deficiency
  4. PubMed: Infant formula vitamin deficiency outbreak
  5. PubMed: Shoshin beriberi infant
  6. PubMed: Israel thiamine outbreak
  7. PubMed: Infantile Wernicke encephalopathy
  8. PubMed: Infant formula regulation vitamin

Back to Table of Contents

Connections

Back to Table of Contents